Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.45 – $1.23
71% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $4.1M | $3.6M | $2.9M | $9.7M | $23.2M | $113.0K | $113.0K |
| Cost of revenue | $893.0K | $905.0K | $1.5M | $924.0K | $2.4M | $15.7M | $1.9M | $1.3M |
| Gross profit | $1.9M | $3.2M | $2.2M | $2.0M | $7.2M | $7.6M | $113.0K | −$1.2M |
| Gross margin | 67.7% | 78.0% | 60.0% | 68.6% | 75.0% | 32.6% | 100.0% | -1031.9% |
| R&D | $3.8M | $5.9M | $9.0M | $13.5M | $11.1M | $14.5M | $14.3M | $16.9M |
| Operating income | −$10.4M | −$11.2M | −$21.3M | −$29.1M | −$32.6M | −$26.7M | −$32.6M | −$30.2M |
| EBITDA | −$7.6M | −$9.1M | −$17.4M | −$26.7M | −$25.9M | −$23.0M | −$17.6M | −$29.0M |
| Net income | −$8.8M | −$9.7M | −$18.9M | −$26.3M | −$39.2M | −$24.9M | −$52.8M | −$38.4M |
| Net margin | -319.5% | -234.9% | -519.6% | -894.8% | -406.0% | -107.3% | -46761.9% | -33961.3% |
| EPS (diluted) | -0.13 | -0.08 | -0.08 | -0.11 | -0.15 | -0.09 | -0.16 | -0.10 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $31M | $-0.07 | $-0.07–$-0.07 | 1 |
| 2027 | $29M | $-0.07 | $-0.07–$-0.07 | 1 |
| 2028 | $187979 | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
AVACTA GROUP PLC ORD NEW
No one on the platform currently holds AVCTF.
No tracked institution reports a position in AVCTF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2018-08-02 | 1-for-100reverse |
No one on the platform has traded AVCTF yet.
| $287M |
| — |
| HLOSFHealios K.K. | $1.80 | +0.00% | $194M | — |
| MDCLFMedinCell S.A. | $34.39 | +0.00% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 11.3× sales vs its 1058.9× historical median P/S.
Fair value ≈ $93.97 · price $1.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.